Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Owner...
May 25 2021 - 2:00PM
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced the launch of CyTOF® XT, designed
to simplify the design and execution of deep cell profiling
studies, standardize sample analysis with reproducible workflows
and automation and accelerate novel therapeutic development to
improve human health.
CyTOF XT™ is the fourth-generation platform in this pioneering
technology. The innovation embedded in this new system simplifies
operation, increases throughput, integrates new sample introduction
automation, improves time to results and reduces total cost of
ownership. These features of CyTOF XT are particularly valuable to
clinical and translational researchers across the pharmaceutical
and biotechnology sectors and the contract research organizations
that serve them.
“The CyTOF XT is essentially an immune profiling workhorse, one
that will bring new capabilities and efficiencies to our
translational research trials,” said Philip Hobson, PhD, Deputy
Head of Flow Cytometry at The Francis Crick Institute in London.
“The combination of the Maxpar® Direct™ Immune Profiling Assay™
with expansion panels, sample barcoding ability, flexible
40-plus-marker panels and reliable run-to-run performance around
the clock will mean we will obtain our results—and ultimately
answers to important research questions— more quickly and
efficiently.
“The automation capabilities of the CyTOF XT mean less hands-on
time, increased sample throughput and more productivity in our core
facility.”The broad adoption of mass cytometry for basic,
translational and clinical research has driven a rapidly growing
bibliography of peer-reviewed publications and use in clinical
research trials. Mass cytometry had been used in more than 150
ongoing or completed National Clinical Trials as of the end of
April 2021.
“Delivering comprehensive data on the human immune system is
increasingly critical to therapy development and clinical
deployment on the journey to improved precision medicine
paradigms,” said Chris Linthwaite, Fluidigm President and CEO.
“Mass cytometry provides the most reliable and reproducible method
to capture the complexity of the human immune system in a
hypothesis-driven approach, and CyTOF XT further simplifies the
process for scaling to larger populations as practitioners shift to
translational and clinical programs.
“CyTOF XT aligns with our Vision 2025 innovation objectives, and
we have secured our first orders through a limited pre-marketing
program pre-launch. This new CyTOF platform offers significant
improvements in throughput, automation, time to results and total
cost of ownership, features that are particularly valuable to
pharma, biotechnology and contract research organizations.
“The CyTOF XT is the latest addition to our award-winning family
of systems, joining Helios™ and the Hyperion™ Imaging System. These
platforms will help researchers advance scientific understanding of
disease and therapies with novel insights into many areas,
including, for example, the function of checkpoint inhibitors, the
impact of drugs on signaling pathways, tumor microenvironment
biology in response to immunotherapy and the efficacy of vaccine
candidates.
“We are excited to launch this new CyTOF platform at a time when
health care innovation has never been more important to combatting
disease and new infectious threats to our global population.”
Learn more: fluidigm.com/cytof.xt
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs
in translational and clinical research, including cancer,
immunology, and immunotherapy. Using proprietary CyTOF and
microfluidics technologies, we develop, manufacture, and market
multi-omic solutions to drive meaningful insights in health and
disease, identify biomarkers to inform decisions, and accelerate
the development of more effective therapies. Our customers are
leading academic, government, pharmaceutical, biotechnology, plant
and animal research, and clinical laboratories worldwide. Together
with them, we strive to increase the quality of life for all. For
more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta, CyTOF, CyTOF XT,
Direct, Helios, Hyperion, Immune Profiling Assay and Maxpar are
trademarks and/or registered trademarks of Fluidigm
Corporation in the United States and/or other
countries. All other trademarks are the sole property of their
respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for
In Vitro Diagnostic Use. It is for Use under Emergency Use
Authorization Only. Rx Only. Other Fluidigm products are provided
for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements for
Fluidigm This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the launch of and anticipated demand for a new product, as well as
the anticipated benefits to customers of, and applications for, the
product and other Fluidigm products. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including but not limited to risks relating to challenges inherent
in developing, manufacturing, launching, marketing, and selling new
products; potential product performance and quality issues;
intellectual property risks; competition; uncertainties in
contractual relationships; and reductions in research and
development spending or changes in budget priorities by customers.
Information on these and additional risks and uncertainties and
other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate
Communications650 243
6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389
6400ir@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024